At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01530 3SBIO
Market Closed 10-09 16:08:08
15.070
+0.080
+0.53%
High15.230Low14.910Vol22.47M
Open15.050D1 Closing14.990Amplitude2.13%
Mkt Cap37.90BTradable Cap37.90BTotal Shares2.52B
T/O338.07MT/O Rate0.89%Tradable Shares2.52B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
3SBIO Repurchases 2.5 Million Shares for HK$37.588 Million on October 9
Stock News  ·  10-09 18:46
3SBIO Repurchases 2.5 Million Shares for HK$37.588 Million on October 9
3SBIO Spends HK$26.5 Million to Repurchase 1.7 Million Shares on October 8
Stock News  ·  10-08 18:22
3SBIO Spends HK$26.5 Million to Repurchase 1.7 Million Shares on October 8
Hong Kong Stock Market Movers: Innovative Drug Stocks Deepen Losses in Afternoon Session, Ascletis Pharma-B (01672) Falls Over 10%, Innovent Bio (01801) Drops Nearly 4%
Stock News  ·  10-08 14:08
Hong Kong Stock Market Movers: Innovative Drug Stocks Deepen Losses in Afternoon Session, Ascletis Pharma-B (01672) Falls Over 10%, Innovent Bio (01801) Drops Nearly 4%
Will Oral Obesity Drug Rights Change 3SBio (SEHK:1530) Narrative
Simply Wall St.  ·  10-07
Will Oral Obesity Drug Rights Change 3SBio (SEHK:1530) Narrative
3SBio Inc.: Citigroup Inc. Disposes of Shares, Long Position Falls to 4.89%
HK Disclosure  ·  10-07
3SBio Inc.: Citigroup Inc. Disposes of Shares, Long Position Falls to 4.89%
3SBio Cuts Outstanding Shares by 10.20 Million in September amid HK$160.96 Million Buy-back, Confirms Public Float Compliance
Bulletin Express  ·  10-02
3SBio Cuts Outstanding Shares by 10.20 Million in September amid HK$160.96 Million Buy-back, Confirms Public Float Compliance
Major Drugmakers Turn to China for Licensing Deals
Reuters  ·  10-02
Major Drugmakers Turn to China for Licensing Deals
Citigroup Inc crosses 5% threshold in 3SBio Inc
HK Disclosure  ·  10-02
Citigroup Inc crosses 5% threshold in 3SBio Inc
Hong Kong Stock Movers: Innovative Drug Stocks Retreat, InnoCare Pharma (09969) Falls Over 8%, RemeGen (09995) Drops Nearly 6%
Stock News  ·  10-02
Hong Kong Stock Movers: Innovative Drug Stocks Retreat, InnoCare Pharma (09969) Falls Over 8%, RemeGen (09995) Drops Nearly 6%
Movement Alert｜3SBIO Falls 5.61% in Regular Trading, Trading at 15.58 HKD
Market Focus  ·  10-02
Movement Alert｜3SBIO Falls 5.61% in Regular Trading, Trading at 15.58 HKD
Major Drugmakers Turn to China for Licensing Deals
Reuters  ·  09-30
Major Drugmakers Turn to China for Licensing Deals
3SBio H1 2026: Revenue Rises 3.9% on Pfizer Milestone, Yet Core Drug Pressure Cuts Profit
Bulletin Express  ·  09-30
3SBio H1 2026: Revenue Rises 3.9% on Pfizer Milestone, Yet Core Drug Pressure Cuts Profit
3SBIO Shares Rise Over 3% as Subsidiary Mandy Partners with MindRank for Exclusive MDR-001 Collaboration
Stock News  ·  09-30
3SBIO Shares Rise Over 3% as Subsidiary Mandy Partners with MindRank for Exclusive MDR-001 Collaboration
Mindrank AI: Collaboration Covers Mainland China, Hong Kong and Macau, with a Total Potential Transaction Value of up to RMB 1.75 Bln (USD 260 Mln)
THOMSON REUTERS  ·  09-28
Mindrank AI: Collaboration Covers Mainland China, Hong Kong and Macau, with a Total Potential Transaction Value of up to RMB 1.75 Bln (USD 260 Mln)
Mindrank AI Ltd : Partners with 3SBio to Commercialize Its AI-Designed Oral Glp-1 in China
THOMSON REUTERS  ·  09-28
Mindrank AI Ltd : Partners with 3SBio to Commercialize Its AI-Designed Oral Glp-1 in China
Mindrank AI: Will be Eligible for up to RMB 1.6 Bln in Additional Milestone Payments
THOMSON REUTERS  ·  09-28
Mindrank AI: Will be Eligible for up to RMB 1.6 Bln in Additional Milestone Payments
3SBIO Spends HK$20.41 Million to Buy Back 1.3 Million Shares on September 28
Stock News  ·  09-28
3SBIO Spends HK$20.41 Million to Buy Back 1.3 Million Shares on September 28
3SBio Executes HK$20.41 Million On-Market Buyback, Cuts Free-Float by 0.05%
Bulletin Express  ·  09-28
3SBio Executes HK$20.41 Million On-Market Buyback, Cuts Free-Float by 0.05%
Movement Alert｜3SBIO Falls 5.06% in Regular Trading, Biotech Sector Faces Broad Selloff After Recent Rally
Market Focus  ·  09-24
Movement Alert｜3SBIO Falls 5.06% in Regular Trading, Biotech Sector Faces Broad Selloff After Recent Rally
HK Movers | Innovative Drug Stocks Rally Broadly; LEPU BIO, INNOCARE, AKESO Jump Over 7%
Tiger Newspress  ·  09-21
HK Movers | Innovative Drug Stocks Rally Broadly; LEPU BIO, INNOCARE, AKESO Jump Over 7%

Introduction

Company Name.
3SBIO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
3SBio Inc is an investment holding company principally engaged in the development, production, marketing and sale of biopharmaceutical products. The Company's main products include biopharmaceuticals such as TPIAO, EPIAO, Yisaipu, and Cipterbin, as well as small moleculessuch as Mandi and Remitch. The Company is also engaged in the contract development and manufacturing operations (CDMO) business that provides customers with research, development and production of a variety of biopharmaceuticals and therapeutic technology platform services. The Company's products are mainly used for chemotherapy-induced thrombocytopenia (CIT), anemia caused by chronic kidney disease (CKD), treatment of chemotherapy-induced anemia (CIA), ankylosing spondylitis (AS) and psoriasis. The Company mainly operates its businesses in the domestic and overseas markets.
Issue price:
--